Burning Rock Biotech
BNR
19 hedge funds and large institutions have $18.7M invested in Burning Rock Biotech in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 11 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.08% less ownership
Funds ownership: 2.52% → 2.44% (-0.08%)
7% less capital invested
Capital invested by funds: $20.1M → $18.7M (-$1.44M)
32% less funds holding
Funds holding: 28 → 19 (-9)
75% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 8
82% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$179K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$10.1K |
| 3 |
BTI
Blue Trust Inc
Alpharetta,
Georgia
|
+$607 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$120 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$252K |
| 2 |
Millennium Management
New York
|
-$164K |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$152K |
| 4 |
LPU
Lansdowne Partners (UK)
London,
United Kingdom
|
-$119K |
| 5 |
EL
EWA LLC
Pittsbugh,
Pennsylvania
|
-$36.8K |
BNR Hedge Fund Activity: Q4 2023 in Review
19 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Burning Rock Biotech (BNR) for Q4 2023, worth a combined $18.7M — down 7.2% from $20.1M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of BNR and 2 opened new positions — a net loss of 9 holders — while 8 trimmed existing stakes and 2 added.
The largest buyer was Kynam Capital Management, adding an estimated $179K. The largest seller was Barclays, exiting entirely with an estimated $252K sold.
- 19 institutional investors held Burning Rock Biotech (BNR) as of Q4 2023, down from 28 in Q3 2023.
- Funds reported $18.7M of Burning Rock Biotech stock for Q4 2023, down 7.2% quarter-over-quarter.
- 2 funds opened new Burning Rock Biotech positions in Q4 2023 and 11 closed out, a net change of -9 holders.
- The largest Burning Rock Biotech buyer in Q4 2023 was Kynam Capital Management, an estimated $179K added.
- The largest Burning Rock Biotech seller in Q4 2023 was Barclays, an estimated $252K sold.
Based on aggregated 13F filings for Q4 2023.